An open-label long-term naturalistic study of mirtazapine treatment for depression in cancer patients

Clinical Drug Investigation

Volumn 28, Issue 2, 2008, Pages 113-120

  Ersoy, Mehmet A ^a,b   Noyan, Aysin M ^a   Elbi, Hayriye ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b EGE UNIVERSITY   (Turkey)

Author keywords

Cancer; Depression; Mirtazapine, therapeutic use; Tetracyclic antidepressants, therapeutic use

Indexed keywords

METHYLPHENIDATE; MIRTAZAPINE; TAMOXIFEN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FATIGUE; FEMALE; FOLLOW UP; HAMILTON SCALE; HEMATOLOGICAL PARAMETERS; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; MALE; NATURALISTIC INQUIRY; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTLESS LEGS SYNDROME; SCORING SYSTEM; SIDE EFFECT; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADULT; AGED; ANOREXIA; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHYLPHENIDATE; MIANSERIN; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 38349177462     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200828020-00005     Document Type: Article

References (33)

1. Fawzy I, Grenberg DB. Oncology. In: Rundell Jr WMG, editor. Textbook of consultation liaison psychiatry. Washington, DC: American Psychiatric Press, 1996: 673-94
2. Carroll BT, Kathol RG, Noyes Jr R, et al. Screening for depression and anxiety in cancer patients using the Hospital Anxiety and Depression Scale. Gen Hosp Psychiatry 1993; 15 (2): 69-74
3. Lederberg M, Holland JC. Psycho-oncology. In: Kaplan HI, Sadock BJ, editors. Comprehensive textbook of psychiatry. Baltimore (MD): Williams and Wilkins, 1995: 1570-92
4. Breitbart W, Jaramillo JR, Chochinov HMC. Palliative and terminal care. In: Holland JC, editor. Psychooncology. New York: Oxford University Press, 1998: 437-49
5. Pirl WF. Evidence report on the occurrence, assessment, and treatment of depression in cancer patients. J Cancer Inst Monogr 2004; 32: 32-9
6. van Heeringen K, Zivkov M. Pharmacological treatment of depression in cancer patients: a placebo-controlled study of mianserin. Br J Psychiatry 1996; 169: 440-3
7. Williams S, Dale J. The effectiveness of treatment for depression/ depressive symptoms in adults with cancer: a systematic review. Br J Cancer 2006; 94: 372-90
8. Waring WS, Good AM, Bateman DN. Lack of significant toxicity after mirtazapine overdose: a five year review of cases admitted to a regional toxicology unit. Clin Toxicol 2007; 45: 45-50
9. Way CM. Safety of newer antidepressants in pregnancy. Pharmacotherapy 2007; 27: 546-52
10. Hannan N, Hamzah Z, Akinpeloye HO, et al. Venlafaxine mirtazapine combination in the treatment of persistent depressive illness. J Psychopharmacol 2007; 21: 161-4
11. Schule C, Baghai TC, Eser D, et al. Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4 week open label parallel group study. World J Biol Psychiatry 2007; 8: 112-22
12. Poyurovsky M, Pashinian A, Weizman R, et al. Low dose mirtazapine: a new option in the treatment of antipsychotic induced akathisia: a randomized, double blind placebo and propranolol controlled trial. Biol Psychiatry 2006; 59: 1071-7
13. Ranjan S, Chandra PS, Chaturvedi SK, et al. Atypical anti-psychotic induced akathisia with depression: therapeutic role of mirtazapine. Ann Pharmacother 2006; 40: 771-4
14. Brunnauer A, Laux G, Geiger E, et al. Antidepressants and driving ability: results from a clinical study. J Clin Psychiatry 2006; 67: 1776-81
15. Stimmel GL, Gutierrez MA. Sexual dysfunction and psychotropic medications. CNS Spectr 2006; 11: 24-30
16. Raji MA, Barnum PD, Freeman J, et al. Mirtazapine for depression and comorbidities in older patients with cancer. Ann Pharmacother 2007; 41: 1548-9
17. de Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol 1995; 10 Suppl. 4: 19-23
18. DeVane CL. Pharmacokinetics of the newer antidepressants: clinical relevance. Am J Med 1994; 97 (6A): 13S-23S
19. Kasper S, Praschak-Rieder N, Tauscher J, et al. A risk-benefit assessment of mirtazapine in the treatment of depression. Drug Saf 1997; 17 (4): 251-64
20. Owen JR, Nemeroff CB. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. Depress Anxiety 1998; 7 Suppl. 1: 24-32
21. Pae CU. Low dose mirtazapine may be successful treatment option for severe nausea and vomiting. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1143-5
22. Remeron (mirtazapine). In: Physicians's desk reference. 53rd ed. Montvale (NJ): Medical Economics Company, 1999
23. Kast RE. Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy. Support Care Cancer 2001; 9 (6): 469-70
24. Theobald DE, Kirsh KL, Holtsclaw E, et al. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage 2002; 23 (5): 442-7
25. Pasquini M, Biondi M, Costantini A, et al. Detection and treatment of depressive and anxiety disorders among cancer patients: feasibility and preliminary findings from a liaison service in an oncology division. Depress Anxiety; 2006; 23 (7): 441-8
26. Greenhouse SW, Geisser, S. On methods in the analysis of profile data. Psychometrika 1959; 24: 95-112
27. Savard J, Morin CM. Insomnia in the context of cancer: a review of a neglected problem. J Clin Oncol 2001; 19 (3): 895-908
28. Thompson DS. Mirtazapine for the treatment of depression and nausea in breast and gynecological oncology. Psychosomatics 2000; 41: 356-9
29. Perez DG, Loprinzi CL, Barton DL, et al. Pilot evaluation of mirtazapine for the treatment of hot flashes. J Support Oncol 2004; 2 (1): 50-6
30. Pirl WF, Roth AJ. Diagnosis and treatment of depression in cancer patients. Oncology (Huntingt) 1999; 13 (9): 1293-301
31. Angelino AF, Treisman GJ. Major depression and demoralization in cancer patients: diagnostic and treatment considerations. Support Care Cancer 2001; 9 (5): 344-9
32. Kast RE, Foley KF. Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur J Cancer Care (Engl) 2007; 16 (4): 351-4
33. Raji MA. Management of chemotherapy-induced side-effects [letter]. Lancet Oncol 2005; 6 (6): 357